TSHA
Closed
Taysha Gene Therapies inc
2.04
-0.07 (-3.32%)
Last Update: 06 Sep 2024 23:04:00
Yesterday: 2.11
Day's Range: 1.99 - 2.13
Send
sign up or login to leave a comment!
When Written:
0.6827
Taysha Gene Therapies Inc is a clinical-stage gene therapy company that is focused on developing and commercializing transformative gene therapies for the treatment of severe and life-threatening neurological diseases. The company was founded in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies is working on developing gene therapies for a range of neurological disorders, including Rett syndrome, GM2 gangliosidosis, CLN1 disease, and SURF1-associated Leigh syndrome. The company's lead product candidate, TSHA-101, is a gene therapy for the treatment of Rett syndrome, a rare genetic disorder that affects brain development and function.
Taysha Gene Therapies is backed by leading life sciences investors, including Fidelity Management & Research Company, Venrock Healthcare Capital Partners, and Blackstone Life Sciences. The company has also established partnerships with academic institutions and research organizations to advance its gene therapy programs.
Taysha Gene Therapies is committed to bringing innovative gene therapies to patients with severe and life-threatening neurological diseases. The company's mission is to transform the lives of patients and families affected by these devastating diseases through the power of gene therapy.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Taysha Gene Therapies is working on developing gene therapies for a range of neurological disorders, including Rett syndrome, GM2 gangliosidosis, CLN1 disease, and SURF1-associated Leigh syndrome. The company's lead product candidate, TSHA-101, is a gene therapy for the treatment of Rett syndrome, a rare genetic disorder that affects brain development and function.
Taysha Gene Therapies is backed by leading life sciences investors, including Fidelity Management & Research Company, Venrock Healthcare Capital Partners, and Blackstone Life Sciences. The company has also established partnerships with academic institutions and research organizations to advance its gene therapy programs.
Taysha Gene Therapies is committed to bringing innovative gene therapies to patients with severe and life-threatening neurological diseases. The company's mission is to transform the lives of patients and families affected by these devastating diseases through the power of gene therapy.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!